Literature DB >> 24244898

MAGE-A3-specific anticancer immunotherapy in the clinical practice.

Vincent G Brichard1, Quentin Godechal.   

Abstract

Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant melanoma antigen family A3 (MAGE-A3) and different immunostimulants exert clinical anticancer activity. In particular, the combination of recombinant MAGE-A3 and AS15, a multicomponent immunostimulant, was found to elicit robust antigen-specific immune responses.

Entities:  

Keywords:  MAGE-A3; biomarkers; cancer; immunization; immunotherapy

Year:  2013        PMID： 24244898      PMCID： PMC3827067          DOI： 10.4161/onci.25995

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  8 in total

1.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

2.  Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Authors:  Wim H J Kruit; Stefan Suciu; Brigitte Dreno; Laurent Mortier; Caroline Robert; Vanna Chiarion-Sileni; Michele Maio; Alessandro Testori; Thierry Dorval; Jean-Jacques Grob; Juergen C Becker; Alan Spatz; Alexander M M Eggermont; Jamila Louahed; Frédéric F Lehmann; Vincent G Brichard; Ulrich Keilholz
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

3.  Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

Authors:  Johan Vansteenkiste; Marcin Zielinski; Albert Linder; Jubrail Dahabreh; Emilio E Gonzalez; Wojciech Malinowski; Marta Lopez-Brea; Tonu Vanakesa; Jacek Jassem; Haralabos Kalofonos; Jakub Perdeus; Reiner Bonnet; Jazeps Basko; Richard Janilionis; Bernward Passlick; Tom Treasure; Marc Gillet; Frédéric F Lehmann; Vincent G Brichard
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

4.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Authors:  Fernando Ulloa-Montoya; Jamila Louahed; Benjamin Dizier; Olivier Gruselle; Bart Spiessens; Frédéric F Lehmann; Stefan Suciu; Wim H J Kruit; Alexander M M Eggermont; Johan Vansteenkiste; Vincent G Brichard
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

5.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

6.  Structure, chromosomal localization, and expression of 12 genes of the MAGE family.

Authors:  E De Plaen; K Arden; C Traversari; J J Gaforio; J P Szikora; C De Smet; F Brasseur; P van der Bruggen; B Lethé; C Lurquin
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

7.  Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.

Authors:  Takemasa Tsuji; Nasser K Altorki; Gerd Ritter; Lloyd J Old; Sacha Gnjatic
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

Review 8.  Human cancer regression antigens.

Authors:  Pia Kvistborg; Marit M van Buuren; Ton N Schumacher
Journal:  Curr Opin Immunol       Date:  2013-04-06       Impact factor: 7.486
  8 in total
  9 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

2.  CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors.

Authors:  Mariana Bonjiorno Martins; Marjory Alana Marcello; Fernando de Assis Batista; Lucas Leite Cunha; Elaine Cristina Morari; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  J Immunol Res       Date:  2014-11-04       Impact factor: 4.818

3.  Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.

Authors:  Xinfeng Chen; Liping Wang; Jinyan Liu; Lan Huang; Li Yang; Qun Gao; Xiaojuan Shi; Jieyao Li; Feng Li; Zhen Zhang; Song Zhao; Bin Zhang; Pierre Van der Bruggen; Yi Zhang
Journal:  Oncol Lett       Date:  2017-02-01       Impact factor: 2.967

4.  MAGE-A Antigens and Cancer Immunotherapy.

Authors:  Paul Zajac; Elke Schultz-Thater; Luigi Tornillo; Charlotte Sadowski; Emanuele Trella; Chantal Mengus; Giandomenica Iezzi; Giulio C Spagnoli
Journal:  Front Med (Lausanne)       Date:  2017-03-08

5.  Targeted photodynamic therapy of cancer using a novel gallium (III) tris (ethoxycarbonyl) corrole conjugated-mAb directed against cancer/testis antigens 83.

Authors:  Ziyu Ye; Yanfang Liang; Yan Ma; Bihua Lin; Longbin Cao; Bin Wang; Zhao Zhang; Haibo Yu; Jixia Li; Mingyuan Huang; Keyuan Zhou; Qunzhou Zhang; Xinguang Liu; Jincheng Zeng
Journal:  Cancer Med       Date:  2018-06-01       Impact factor: 4.452

Review 6.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

7.  Trial Watch: Toll-like receptor agonists in oncological indications.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Isabelle Cremer; Jan Henrik Ter Meulen; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-08-01       Impact factor: 8.110

Review 8.  Trends and advances in tumor immunology and lung cancer immunotherapy.

Authors:  Mohanad Aldarouish; Cailian Wang
Journal:  J Exp Clin Cancer Res       Date:  2016-09-29

9.  Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.

Authors:  Carol Sze Ki Leung; Benoit J Van den Eynde; James McAuliffe; Hok Fung Chan; Laurine Noblecourt; Ramiro Andrei Ramirez-Valdez; Vinnycius Pereira-Almeida; Yaxuan Zhou; Emily Pollock; Federica Cappuccini; Irina Redchenko; Adrian Vs Hill
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.